On Tuesday, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) opened lower -6.92% from the last session, before settling in for the closing price of $0.74. Price fluctuations for IRWD have ranged from $0.53 to $7.11 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -47.49% annually for the last half of the decade. Company’s average yearly earnings per share was noted 1644.75% at the time writing. With a float of $155.76 million, this company’s outstanding shares have now reached $161.81 million.
In an organization with 253 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 99.69%, operating margin of 17.25%, and the pretax margin is 7.54%.
Ironwood Pharmaceuticals Inc (IRWD) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Ironwood Pharmaceuticals Inc is 3.74%, while institutional ownership is 97.51%. The most recent insider transaction that took place on May 16 ’25, was worth 7,745. In this transaction Chief Executive Officer of this company sold 13,353 shares at a rate of $0.58, taking the stock ownership to the 1,147,281 shares. Before that another transaction happened on May 16 ’25, when Company’s Chief Commercial Officer sold 2,563 for $0.58, making the entire transaction worth $1,487. This insider now owns 242,596 shares in total.
Ironwood Pharmaceuticals Inc (IRWD) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 1644.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 141.01% during the next five years compared to -47.49% drop over the previous five years of trading.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Trading Performance Indicators
Check out the current performance indicators for Ironwood Pharmaceuticals Inc (IRWD). In the past quarter, the stock posted a quick ratio of 3.34. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.35. Likewise, its price to free cash flow for the trailing twelve months is 1.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.20, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.35 in one year’s time.
Technical Analysis of Ironwood Pharmaceuticals Inc (IRWD)
Let’s dig in a bit further. During the last 5-days, its volume was 1.1 million. That was inferior than the volume of 3.13 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 33.18%.
During the past 100 days, Ironwood Pharmaceuticals Inc’s (IRWD) raw stochastic average was set at 10.78%, which indicates a significant decrease from 11.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0605 in the past 14 days, which was lower than the 0.0982 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6925, while its 200-day Moving Average is $2.3740. However, in the short run, Ironwood Pharmaceuticals Inc’s stock first resistance to watch stands at $0.7294. Second resistance stands at $0.7719. The third major resistance level sits at $0.8015. If the price goes on to break the first support level at $0.6573, it is likely to go to the next support level at $0.6277. The third support level lies at $0.5852 if the price breaches the second support level.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Key Stats
There are currently 161,820K shares outstanding in the company with a market cap of 111.17 million. Presently, the company’s annual sales total 351,410 K according to its annual income of 880 K. Last quarter, the company’s sales amounted to 41,140 K and its income totaled -37,390 K.
